Hubei Biocause Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Wenxia Zhou
Chief executive officer
CN¥2.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.6yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 29% Bounce
Dec 16
Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story
Oct 23Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce
Sep 05Improved Revenues Required Before Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Find Their Feet
Jun 10Fewer Investors Than Expected Jumping On Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627)
Mar 05CEO
Wenxia Zhou (52 yo)
4.6yrs
Tenure
CN¥2,015,000
Compensation
Ms. Wenxia Zhou serves as Vice Chairman and Director of Hubei Biocause Pharmaceutical Co., Ltd since June 12, 2020 and its General Manager May 26, 2020.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & GM | 4.5yrs | CN¥2.02m | no data | |
| CFO & Director | 4.5yrs | CN¥651.00k | no data | |
| Secretary of the Board & Non-Independent Director | 4.5yrs | CN¥301.00k | no data | |
| Chairman of the Board of Directors | 9.8yrs | no data | 10.47% CN¥ 2.6b | |
| Chairman of the Supervisory Board | 6.7yrs | no data | no data | |
| Employee Supervisor | 4.7yrs | no data | no data | |
| Supervisor | 1.6yrs | no data | no data |
4.5yrs
Average Tenure
52yo
Average Age
Experienced Board: 000627's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 07:47 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Biocause Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Liu | Changjiang Securities Co. LTD. |
| Yeyong Meng | SWS Research Co., Ltd. |